GL1X · GenesisL1 explorer

Research workbench

Catalytic domain of human phosphodiesterase 4B2B in complex with a quinoline inhibitor

Analyse Catalytic domain of human phosphodiesterase 4B2B in complex with a quinoline… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
3FRG
Type
protein
Length
335 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Camp-specific 3',5'-cyclic phosphodiesterase 4B
EC
3.1.4.17
UniProt
Q07343
Ligands
SK4, ARS, ZN, MG
Pockets
3 · best druggability 0.71

Structure

x-ray diffraction · 1 distinct chain · 67% helix, 1% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ACamp-specific 3',5'-cyclic phosphodiesterase 4B (EC 3.1.4.17)protein33567% helix, 1% strandQ07343

Ligands and binding sites

  • SK4 · 4-[(3-methoxyphenyl)amino]-6-(methylsulfonyl)quinoline-3-carboxamide · ligand · chains A
  • ARS · Arsenic · metal · 3 copies · chains A
  • ZN · Zinc ion · metal · chains A
  • MG · Magnesium ion · metal · chains A
  • GOL · Glycerol · additive · 2 copies · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
15080.710.8149SK4, MG, ARS
2550.370.7917ARS
3600.330.7718empty

Compared structures

  • 3FRG · Catalytic Domain of Human Phosphodiesterase 4B2B in Complex with a Quinoline Inhibitor · the same entry in another collection · chain A against A, TM-score 1.00
  • Q07343 · AlphaFold monomer V2.0 prediction for camp-specific 3',5'-cyclic phosphodiesterase 4B… · a predicted model of the same protein · chain A against A, TM-score 0.98

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.